December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Disc Medicine, Inc. - Common Stock (NQ:IRON)

69.76 +1.64 (+2.41%)
Official Closing Price Updated: 4:15 PM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Disc Medicine, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Integra LifeSciences Posts Upbeat Results, Joins Air Transport Services, Freshpet, Yum China And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Dr. Rahul Rajan Kaushik is an accomplished technical operations leader with over two decades of expertise in Chemistry, Manufacturing and Controls (CMC) 
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Dr. Steve Caffé is an accomplished industry executive with over 25 years of expertise in global product development and regulatory affairs 
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in Upcoming Investor Conferences
From Disc Medicine Inc
Via GlobeNewswire
News headline image
IRON Stock Earnings: Disc Medicine Beats EPS for Q2 2024 ↗
IRON stock results show that Disc Medicine beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
S&P 500 Edges Lower; RH Shares Plunge After Q1 Results ↗
 
Via Benzinga
Topics Stocks
News headline image
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Gains 1%; US Consumer Sentiment Falls In June ↗
 
Via Benzinga
News headline image
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Disc Medicine Announces Underwritten Offering of Common Stock
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
From Disc Medicine Inc
Via GlobeNewswire
News headline image
IRON Stock Earnings: Disc Medicine Misses EPS for Q1 2024 ↗
IRON stock results show that Disc Medicine missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
From Disc Medicine Inc
Via GlobeNewswire
News headline image
Top 3 Health Care Stocks You'll Regret Missing This Month ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Gold Gains 1%; CXApp Shares Spike Higher ↗
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.3% on Monday. The Dow traded down 0.67% to 39,538.91 while the NASDAQ fell 0.06% to 16,369.44. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
News headline image
Crude Oil Moves Higher; Oxford Industries Shares Fall After Q4 Results ↗
U.S. stocks traded lower midway through trading, with the Dow Jones falling over 300 points on Monday. The Dow traded down 0.79% to 39,492.80 while the NASDAQ fell 0.22% to 16,344.11. The S&P 500 also... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Disc Medicine Stock Plunges As Light Sensitivity Treatment Data Confounded Due To Outsized Placebo Response ↗
Disc Medicine releases AURORA Phase 2 study data on bitopertin for Erythropoietic Protoporphyria. Significant reductions in PPIX levels and improvements in phototoxic reactions observed with bitopertin... 
Via Benzinga
News headline image
Disc Medicine Plummets 59% After Placebo Effect Confounds Sunlight Sensitivity Study ↗
The company is hoping to treat a rare disease that causes patients to experience severe reactions to sunlight. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.